Clune & Associates, Ltd. Acumen Pharmaceuticals, Inc. Transaction History
Clune & Associates, Ltd.
- $365 Billion
- Q2 2025
A detailed history of Clune & Associates, Ltd. transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Clune & Associates, Ltd. holds 16,500 shares of ABOS stock, worth $23,430. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,500
Previous 16,500
-0.0%
Holding current value
$23,430
Previous $18.2 Million
5.45%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ABOS
# of Institutions
83Shares Held
38.7MCall Options Held
39.1KPut Options Held
53.4K-
Ra Capital Management, L.P. Boston, MA14.9MShares$21.2 Million0.34% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$4.85 Million1.6% of portfolio
-
Franklin Resources Inc San Mateo, CA3.14MShares$4.46 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$3.07 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$2.75 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $57.5M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...